2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Non-Biological Therapies, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Bleeding and Clotting, Platelet Disorders, Genetic Disorders, Immunology, Autoimmune Disorders, Infectious Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

3856 Clinical activity and single-cell multi-omics profiling of a short course of lisaftoclax (APG-2575) plus azacitidine in patients with myelodysplastic neoplasms: Results from a pilot study

Yingwan Luo, MD, PhD, Wei Wang, PhD2, Mixue Xie3, Hongyan Tong, MD, PhD4
1 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
3 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
4 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Background: Myelodysplastic neoplasms (MDS) are clinically and molecularly heterogeneous, and outcomes remain poor in high-risk disease. CR rates with hypomethylating agent (HMA)-based regimens are generally ~15-25%, underscoring the need for more effective and tolerable approaches. In real-world practice, older patients or those with prior malignancies, infections, or other comorbidities may be ineligible for transplant, unable to tolerate prolonged BCL-2 inhibitor exposure, or excluded from conventional trials. Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with a short half-life (~4-5 h), which may enable a controllable short-course strategy. We evaluated 7-day APG-2575 plus azacitidine (AZA) in high-risk MDS and used paired single-cell multi-omics to explore biomarkers and mechanisms of benefit.

Methods: Patients with MDS treated with APG-2575 plus AZA were included. In cycle 1, APG-2575 was given orally with ramp-up (200 mg day 1, 400 mg day 2, 600 mg days 3-7) plus AZA 75 mg/m2 subcutaneously days 1-7. From cycle 2, APG-2575 600 mg days 1-7 plus AZA days 1-7 was repeated. Patients without response after 2 cycles discontinued therapy; responders continued until loss of response or unacceptable toxicity. Responses were assessed by IWG 2023 criteria. CRc was defined as CR + CRh + CRL + CR equivalent, and ORR as CRc + HI + PR. For single-cell analyses, bone marrow mononuclear cells from 22 longitudinal samples from 8 patients and 9 healthy donor (HD) samples were profiled by scFAST-seq (31 samples total), integrating whole-transcriptome single-cell RNA sequencing with targeted mutation profiling. Cell populations were annotated by canonical markers, and mutation calls were mapped across HSC/MPP subclusters.

Results

As of July 29, 2026, 20 patients had received short-course APG-2575 plus AZA. Median follow-up was 6.5 months (range, 1-11), and maximum exposure was 9 cycles. The cohort was clinically challenging: 40.0% (8/20) were >70 years, 10.0% (2/20) had prior malignancies, and 20.0% (4/20) had concurrent infection or severe comorbidities. IPSS-R high/very high risk was present in 80.0% (16/20), and IPSS-M high/very high risk in 95.0% (19/20).

The ORR was 70.0% (14/20), including CRc in 55.0% (11/20) and CR in 30.0% (6/20). Molecular subgroups showed distinct outcomes. Patients with TP53 mutation had an ORR and CRc rate of 28.6% (2/7). In contrast, non-TP53-mutant patients had an ORR of 92.3% (12/13), CRc rate of 69.2% (9/13), and CR rate of 38.5% (5/13). All RUNX1-mutant patients responded (ORR 100%, 6/6), including CR in 66.7% (4/6) and HI in 33.3% (2/6), suggesting that RUNX1 mutation may mark a subgroup more likely to benefit. Safety with hematologic recovery data are being updated.

Given the encouraging clinical activity of APG-2575 plus AZA observed in this pilot study, we performed single-cell analyses. After quality control, 378,168 cells were retained and classified into 16 major hematopoietic/immune populations. Treatment was associated with reductions in HSC/MPP and pDC populations and increases in erythroid cells and megakaryocyte-erythroid progenitors, with the largest shift in HSC/MPP. Among 20,776 HSC/MPP cells, 14 subclusters were identified, including several restricted to MDS. HSC/MPP composition was relatively consistent across HDs but heterogeneous across MDS samples. In responders, dominant HSC/MPP subclusters contracted after treatment and shifted toward a less dominated, more HD-like composition; this pattern was not seen in the non-responder.

Single-cell-derived VAF estimates correlated strongly with adjusted target-NGS VAF (UMI-based Pearson r=0.82; cell-rate-based r=0.83; both P<0.001; n=55), supporting mutation assignment at single-cell resolution. RUNX1- and STAG2-mutant cells preferentially localized to HSC_C01 and HSC_C11, whereas TP53-mutant cells were enriched in MDS-specific subclusters (C03, C08, C14). Clinical response was accompanied by depletion of mutation-defined populations. In RUNX1-mutant patients, RUNX1-mutant HSC/MPP cells decreased in number and proportion after treatment and became undetectable at CR.

Conclusions

Short-course APG-2575 plus AZA showed encouraging activity in this pilot MDS cohort, with especially promising responses in RUNX1-mutant patients. Paired scFAST-seq linked response to HSC/MPP remodeling and clearance of mutation-defined populations, supporting further evaluation of this regimen and single-cell biomarkers to identify patients most likely to benefit.

Yingwan Luo, MD, PhD: No relevant conflicts of interest to declare.